Breakthrough Designations

Breakthrough status was introduced in the 2012 FDA Safety and Innovation Act to expedite development and review of products for serious medical needs when preliminary evidence indicates that the agent may provide substantial improvement over existing therapies on one or more clinically significant endpoints. Updated weekly.